Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018
American Journal of Epidemiology · 2025
DOI: 10.1093/aje/kwae268 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Rob F Walker und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, United States. Hauptthemen laut MEDLINE: Venous Thromboembolism, Anticoagulants, Rivaroxaban, Warfarin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Direct oral anticoagulants (DOACs; namely, rivaroxaban and apixaban) and warfarin are approved for venous thromboembolism (VTE) treatment. Few direct comparisons exist of DOACs on risk of death among patients with VTE, and for patients with concomitant conditions (eg, kidney disease, liver disease), clinical guidelines are unclear. We evaluated 6-month all-cause mortality by anticoagulant prescribed for primary treatment of VTE. Using data from a 20% sample of Medicare beneficiaries, we created a propensity score–matched analytic data set of 47 860 beneficiaries with noncancer incident VTE. We used Cox regression to estimate adjusted hazard ratios (HRs) of OACs with 6-month mortality, and tested interactions by liver and kidney disease. There were 3422 deaths over 6 months of follow-up. In adjusted models, patients prescribed rivaroxaban (HR = 0.82; 95% CI, 0.76-0.90) had lower mortality rates than those prescribed warfarin. There was no association when comparing apixaban with warfarin (HR = 0.96; 95% CI, 0.87-1.07). In head-to-head comparisons of apixaban and rivaroxaban, the HR was 1.14 (95% CI, 1.01-1.28). Findings were similar among patients with liver and kidney disease. Overall, risk of death was similar by OAC prescribed. Though it is possible residual confounding remained, there was some suggestion of lower risk with rivaroxaban than warfarin. Treatment with DOACs appears safe among patients with VTE who have concomitant kidney or liver disease. This article is part of a Special Collection on Pharmacoepidemiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, United States.
- Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States.
- Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
ORCID-Profile: Rob F Walker, Neil A Zakai, Richard F Maclehose, Faye L Norby, Alvaro Alonso, Pamela L Lutsey
Förderung
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Walker, R. F., Zakai, N. A., Maclehose, R. F., Norby, F. L., Alonso, A., & Lutsey, P. L. (2025). Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae268
Vancouver
Walker RF, Zakai NA, Maclehose RF, Norby FL, Alonso A, Lutsey PL. Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwae268
BibTeX
@article{Walker2025,
author = {Walker, Rob F and Zakai, Neil A and Maclehose, Richard F and Norby, Faye L and Alonso, Alvaro and Lutsey, Pamela L},
title = {Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018},
journal = {American Journal of Epidemiology},
year = {2025},
doi = {10.1093/aje/kwae268}
}
EUVIMED